Waseem Ahmad, MD
Neurology · Davenport, IANPI 1124063375
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,722 of the $17,172 with a category attached, or 62.4%. It is spread thinly across 52 manufacturers, the largest accounting for just 18.8%. 2025 is the largest year on record at $4,627, 3.2 times the $1,430 reported in 2019. Among neurology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 596 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Globus Medical$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Livanova USA, Inc.$1K
- Harmony Biosciences LLC$865
- plus $7K from 46 others
What the payments were for
- Consulting fees$1,67510%
- Speaking & faculty fees$1,2377%
- Travel & lodging$2,70516%
- Food & beverage$10,72262%
- Education$8335%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ExcelsiusGPS Robotic Navigation System$2,062
- NURTEC ODT$1,525
- ZAVZPRET$1,220
- VNS - Sentiva$822
- TYSABRI$150
- WatchPATONE$129
- VYVGART$125
- VYEPTI$111
- Wakix$105
How this compares
$17,172 in reported general payments places this provider in the 90th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 60 | $70,737 |
| Aimovig AutoinjectorErenumab-Aooe | 85 | $69,716 |
| AptiomEslicarbazepine Acetate | 41 | $53,085 |
| GlatopaGlatiramer Acetate | 16 | $46,905 |
| Emgality PenGalcanezumab-Gnlm | 47 | $38,490 |
| UbrelvyUbrogepant | 29 | $32,502 |
| Nurtec OdtRimegepant Sulfate | 22 | $31,310 |
| Memantine Hcl | 553 | $12,648 |
| Levetiracetam | 280 | $9,008 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 116 | $6,472 |
| Gabapentin | 293 | $4,491 |
| Memantine Hcl ErMemantine Hcl | 50 | $4,126 |
| Divalproex Sodium | 53 | $3,472 |
| Carbamazepine ErCarbamazepine | 16 | $3,256 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 223 | $3,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,317 | $103,23989 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $50 | $53,08541 claims |
| PfizerNurtec Odt | $3,228 | $31,31022 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $17 | $3,35656 claims |
| Upsher-smith Laboratories LLCTopiramate | $45 | $1,852198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 neurology providers in Iowa.
Other neurology in Davenport
- Rodney ShortDavenport$6K
- Ruggero SerafiniDavenport$1K
- Irena Charysz BirskiDavenport$1K
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.